To read the full story, subscribe or sign in.

GSK Buying Corixa: $300M Brings MPL Facility, More

May 3, 2005

Vaccine partner GlaxoSmithKline plc plans to buy Corixa Corp. for $300 million in cash, paying $4.40 per share - a 48 percent premium to the closing price on April 28, the day before the deal was made public. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

Illustration of a nerve cell with DNA double helix

Molecular signatures show subtypes in neurodegenerative diseases

BioWorld Science

Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the...

More than two to tango: multispecifics at ESMO TAT

BioWorld Science

Multispecifics took center stage at this year’s ESMO TAT, emerging as one of the hottest trends in oncology research. Unlike traditional small-molecule drugs or...